Video

Importance of Molecular Classification

Molecular classification of tumors with assays like CancerTYPE ID can be beneficial for determining the cancer type in patients with unclear or unknown primary cancers, says F. Anthony Greco, MD. Next-generation sequencing can then be performed using the same biopsy. This can help to guide targeted treatment, including in malignancies of the lung, colon, and breast. Understanding the cancer type and applying the appropriate treatment improves patient outcomes, states Greco.

If CancerTYPE ID results show that a patient has a high probability of having lung cancer, this information can help direct clinicians to look for abnormalities that are common in lung cancer, says Suresh S. Ramalingam, MD. Clinicians may then be able to identify actionable mutations in EGFR or ALK from molecular testing. Physicians should understand the importance of molecular testing in cancers, comments Ramalingam, which is particularly valuable during the time of diagnosis in advanced stage disease.

Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
Alexander I. Spira MD, PhD, FACP, FASCO
In this episode of OncChats: A Close Look at Clinical Trials in Oncology and Beyond, Dr Carvajal discusses the progress made in cancer clinical trials, with nearly 20,000 trials worldwide and over 80 FDA-approved cancer drugs since 2015, while also noting the challenges posed by the increasing complexity of therapies and trial protocols.
Marcella Ali Kaddoura, MD